Coronavirus COVID-19 Medical Science Plays

[Fress]

Phase 3 FDA Covid Trial one of a few drugs in Phase 3

Study Description

Brief Summary:
This is a Phase 3, multi-center, randomized, double blind, placebo controlled, clinical study of bucillamine (2 dosage levels) in patients with mild-moderate COVID-19. Patients will be randomized 1:1:1 to receive bucillamine 100 mg 3 times a day (TID), bucillamine 200 mg TID or placebo TID for up to 14 days. After the first interim analysis when a single dose is selected, patients will then be randomized 2:1 to the selected bucillamine dose or placebo The study will be overseen by an independent Data and Safety Monitoring Board (DSMB). Up to 10 centers in the United States will conduct this study. Up to 1000 patients will be enrolled in this study. Patients will participate in the study approximately 45 days.

https://www.clinicaltrials.gov/ct2/show/NCT04504734?term=Bucillamine&cond=Covid19&draw=2&rank=1

CYDY 1.5 Billion Market cap Phase 2 CV-19 went from .26 to $10.00

RLFTF 1 Billion Market cap Phase 3 CV-19 Drug

RVVTF 40 Million market cap .18 cents Phase 3 CV-19 interim results by end of Dec 2020 low side affects for Bucillamine and cheap to manufacture at scale.

$RVVTF